Figure S2. SmaR represses CRISPR-Cas expression in the absence of QS signals through growth (related to Figure 2).
cas::lacZ and CRISPR::lacZ activity for each of the type I-E, type I-F and type III-A reporter strains in the WT (see Figure  S1 for strain names), smaI mutant (see Figure S1 for strain names), smaR mutant (PCF228, PCF229 and PCF231-235) and smaIR mutant (PCF237, PCF238 and PCF240-244) backgrounds throughout growth. Differences in activity between smaI and all other strains beyond 12 h were statistically significant (P ≤ 0.05) for each reporter except CRISPR3 and CRISPR4 (two-way analysis of variance (ANOVA) with the Bonferroni's multiple comparisons test). Data shown are the mean ± SD (n = 3).
Figure S3. SmaR represses the type I-E, I-F and III-A CRISPR-Cas systems (related to Figure 2).
Normalized cas::lacZ activity in a heterologous system (E. coli CC118 λpir) for each of the (A) type I-E cas8e (pPF714), (B) type I-F cas1 (pPF715), (C) type III-A cas10 (pPF717), (D) type I-E CRISPR1 (pPF861), (E) type I-F CRISPR2 (pPF862), (F) type III-A CRISPR3 (pPF863) and (G) type III-A CRISPR4 (pPF888) promoters ± SmaR (pPF972), at 3 h post induction with 0.1 mM IPTG. (H) Activity of a P. atrosepticum cyaA::lacZ (control) reporter in E. coli CC118 λpir ± SmaR (pPF972), at 3 h post induction. Statistical significance was assessed by unpaired two-tailed t-test (* P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001). Data shown are the mean ± SD (n = 3). Figure S4 . Addition of C4-HSL to the smaI mutant restores wild-type interference and adaptation for each CRISPRCas subtype (related to Figures 3 and 4) . Conjugation efficiency of untargeted control and targeted plasmids for the (A) type I-E (pPF719 control and pPF724 targeted), (B) type I-F (pPF719 control and pPF722 targeted) or (C) type III-A (pPF781 control and pPF1043 targeted) systems in WT (LacA) or smaI (LIS) mutant backgrounds. Conjugation efficiency was scored as transconjugants/recipients. Spacer acquisition (CRISPR expansion) for the WT or smaI mutant strains for either the (D) type I-E (pPF1048 primed) or (E) type I-F (pPF1032 primed) systems. CRISPR arrays were amplified by PCR and analyzed on 3% agarose gels. CRISPR expansion was normalized relative to the expansion observed in the WT control (WT control mean set as 100%). C4-HSL was added at a final concentration of 0.5 µM to the plates and bacterial cultures throughout the experiments and the controls included DMSO solvent. Statistical significance was assessed by unpaired t-test (* P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001). Data shown are the mean ± SD (n = 3). Table S1 . Bacterial strains used in this study (related to Figures 1-4) .
Name
Genotype/Phenotype Reference E. coli CC118 λpir araD, Δ(ara, leu), ΔlacZ74, phoA20, galK, thi-1, rspE, rpoB, argE, recA1, λpir (Herrero et al., 1990 Note: In the oligonucleotide sequences, protospacers are in italics and restriction sites are underlined.
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CRISPR array sequencing
The Serratia sp. ATCC39006 genome has previously been sequenced (Fineran et al., 2013) , but gaps existed at type I-E and I-F CRISPR arrays (CRISPR1 and CRISPR2). The CRISPR1 and CRISPR2 arrays were amplified by PCR from the LacA strain using primer pairs PF565 + PF1834 and PF565 + PF1835, respectively. The products were gel extracted and sequenced by primer walking using primers PF565, PF633, PF1874, PF1875 or PF1905 for CRISPR1 and PF575, PF1835, PF1876, PF1903 or PF1904 for CRISPR2. Assembled reads were mapped to the existing genome (NZ_AWXH00000000) using Geneious v9 (Kearse et al., 2012) . The sequenced arrays were verified by aligning short (36 nt), single-end Illumina reads from the original de novo genome assembly dataset (Fineran et al., 2013) . The CRISPR3 and CRISPR4 arrays were fully assembled in the existing draft sequence.
Construction of cas and CRISPR reporter strains
The cas and CRISPR promoter regions for the type I-E, I-F and III-A systems were each cloned into an integrative lacZ reporter plasmid, pVIK107-Tc (Table S2 ). The promoter regions were amplified by PCR and cloned into pVIK107-Tc using the primers and their respective restriction endonucleases listed in Table S3 . The integrative vectors were introduced into the various Serratia backgrounds by conjugation from the donor strain E. coli S17-1 λpir. Counter-selection for the E. coli donor was achieved using either growth on minimal medium or on LB containing appropriate antibiotics for the Serratia backgrounds. All integrant reporter strains were confirmed by appropriate antibiotic resistance, PCR and sequencing.
Construction of SmaR expression plasmid and heterologous repression assays
A plasmid for heterologous expression of SmaR was generated by PCR amplification of the smaR gene using primers PF1958 and PF1959. The product was digested with BamHI and PstI and cloned into pQE-80LoriT that was cut with the same enzymes, resulting in plasmid pPF972. E. coli CC118 λpir was transformed with either the vector control (pQE80LoriT) or the construct for SmaR expression (pPF972) and with either the control reporter plasmid (pVIK107-Tc) or reporter plasmids for the different cas and CRISPR promoter-lacZ fusions (Table S2 ). Transformants were confirmed by PCR and their antibiotic-resistance profile, and grown at 37°C for β-galactosidase assays as described above.
Construction of interference and priming plasmids
Plasmids that would be targeted or primed by the type I-E and I-F systems were generated as follows. The gene encoding GFPmut3.1 was amplified from pGREENTIR and cloned into the EcoRI and HindIII sites of pQE-80LoriT, to generate pQE80LoriT-GFP. The gene encoding Tc R and either no protospacer (PF1615), a type I-E protospacer (PF1617) or a type I-F protospacer containing a single nucleotide deletion at position 23 (PF1616 and PF2034) was amplified from pTRB31 (Richter et al., 2014) with the reverse primer PF210. Primers PF1617, PF1616 and PF2034 had a variable nucleotide in the type I-E and I-F PAM, respectively, which allowed for cloning of targeted and primed plasmids (see Table S3 ). The PCR products were digested with NcoI and XhoI and ligated into pQE-80L-oriT-GFP cut with BspHI (compatible with NcoI) and XhoI. Plasmids were sequenced and the resulting plasmids were pPF719 (no protospacer control), pPF724 (type I-E targeted), pPF722 (type I-F targeted), pPF1048 (type I-E primed), pPF1032 (type I-F primed), (Table S3) . To construct the type III-A targeted plasmid, we cloned a protospacer complementary to the CRISPR3 spacer 1 into the multiple cloning region a pBAD30 expression vector derivative (pPF781). The pPF781 (naïve control) plasmid was constructed by joining a Cm R cassette with the RP4 OriT from pQE-80LoriT (using overlap PCR with primers PF1698 + PF1700 and PF1699 + PF1701 for the first round, followed by PF1698 + PF1701 in the second round), digesting the product with KpnI and XmaI, and subsequently ligating this with a KpnI/XmaI-digested AraC/P BAD fragment of pBAD30 (generated by PCR using the primers PF1666 + PF610). The protospacer fragment corresponding to CRISPR3 spacer 1 was formed by annealing primers PF2086 and PF2087, which resulted in overlapping sticky ends compatible with the KpnI and SphI sites in the multiple cloning region of pPF781. The resulting construct (pPF1043) encodes the III-A targeted protospacer on the sense strand of the transcript produced from the araBAD promoter.
